CS-NEURO-1

In 2013, we submitted patent application N2010968 in Europe entitled "Composition for the Treatment of Neurobehavioral Disorders". The subject of the patent is development of cannabinoid-based formulations to treat a variety of neurobehavioral disorders, such as attention deficit hyperactivity disorder (ADHD) and anxiety. The first formulation of CS-NEURO-1 in the series of neurobehavioral disorder-targeted products is in pre-clinical development with promising clinical results.  We intend to use the invention in food products through a licensing agreement with a partner company and move forward contemporaneously with pharmaceutical grade development in Europe and North America.